Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Treasury union on FDA lab closures

This article was originally published in The Tan Sheet

Executive Summary

The National Treasury Employees Union announces Feb. 12 it sent a letter to Rep. John Dingell, D-Mich., and Rep. Bart Stupak, D-Mich., to halt proposed FDA Office of Regulatory Affairs lab closures. NTEU President Colleen M. Kelley says in a release the lab closures would compromise food safety. Kelley also says she disapproves of FDA's lack of communication with its employees, "I find it particularly egregious that the agency would let corrosive rumors about closings and consolidations spread throughout the workplace." NTEU's letter follows on the heels of a letter 20 senators sent to FDA Commissioner Andrew C. von Eschenbach in January, saying the lab closures should undergo a congressional review (1"The Tan Sheet," Feb. 5, 2007, p. 13)...

You may also be interested in...



Senators Ask ORA To Halt Lab Closure Pending Congressional Review

The Office of Regulatory Affairs' plan to close FDA labs should "undergo congressional review" according to a letter 20 senators sent to Commissioner Andrew von Eschenbach Jan. 30

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel